Literature DB >> 24138304

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.

Bastian von Tresckow1, Horst Müller, Dennis A Eichenauer, Jan P Glossmann, Andreas Josting, Boris Böll, Beate Klimm, Stephanie Sasse, Michael Fuchs, Peter Borchmann, Andreas Engert.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24138304     DOI： 10.3109/10428194.2013.854888

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.

Authors:  Scott D Ramsey; Auayporn Nademanee; Tamas Masszi; Jerzy Holowiecki; Muneer Abidi; Andy Chen; Patrick Stiff; Simonetta Viviani; John W Sweetenham; John Radford; Yanyan Zhu; Vijayveer Bonthapally; Elizabeth Thomas; Akshara Richhariya; Naomi N Hunder; Jan Walewski; Craig H Moskowitz
Journal:  Br J Haematol       Date:  2016-09-21       Impact factor: 6.998

2.  Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience.

Authors:  Jayastu Senapati; Anup J Devasia; Anu Korula; N A Fouzia; Uday Kulkarni; Kavitha M Lakshmi; Sharon Lionel; Aby Abraham; Alok Srivastava; Vikram Mathews; Biju George
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-27       Impact factor: 0.900

Review 3.  How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.

Authors:  Julia Driessen; Sanne H Tonino; Alison J Moskowitz; Marie José Kersten
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern.

Authors:  Simone Anfossi; George A Calin
Journal:  Am J Pathol       Date:  2016-07-25       Impact factor: 4.307

5.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Authors:  Philippe Armand; Andreas Engert; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John M Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Margaret A Shipp; Kazunobu Kato; Anne Sumbul; Benedetto Farsaci; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544

6.  Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.

Authors:  Jesko Momotow; Helen Goergen; Karolin Behringer; Paul J Bröckelmann; Sven Borchmann; Bastian V Tresckow; Carsten Kobe; Andreas Engert; Stephanie Sasse
Journal:  Hemasphere       Date:  2019-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.